HOME OUR SERVICES

Manufacturing, Science, and Technologies (MSAT)

Translating Breakthrough Medicines From the Bench to the Clinic 
CONTACT US

From Bench to Bedside With BioCentriq's MSAT Team

BioCentriq's MSAT team serves as a hands-on liaison between our partners and our own process development and manufacturing teams, working to consistently improve how therapies are advanced from bench to bedside. 

Our MSAT team is equipped with the technical know-how and regulatory insights to ensure the successful translation of novel processes into the manufacturing suite. We perform quality assessments as early as possible in the product lifecycle and employ Quality-by-Design principles to determine key attributes and parameters critical to the production of high-quality drug products.

Working closely with our partners, we first help identify the Quality Target Product Profile and Critical Quality Attributes (CQA) for the therapeutic. The MSAT team seeks to define the Critical Process Parameters and Critical Material Attributes and key inputs to the process, all based on the CQAs initially identified. 

Our team works closely with biotech companies who have early-stage cell therapy products that are either autologous or allogeneic and rely on a variety of cell lines. Our expertise spans multiple modalities, and our standard approach is designed to ensure successful tech transfer of products in any clinical phase. 

The BioCentriq Approach to MSAT

Image
Deploy a tailored, phase-appropriate approach for technology transfer. 
operational space
Minimize scale up risks with a Quality by Design approach. 
Image
De-risk innovative therapies by using detailed gap assessments. 

Learn More About MSAT at BioCentriq

Our MSAT team combines diverse expertise that's used to bring your product from bench to scale. Learn more about how we optimize tech transfers and utilize a Quality by Design framework to get your product to clinic. 

We have a reliable and adaptable approach to technology transfer that leverages our state-of-the-art facilities and experienced staff to enable successful implementation of at-scale manufacturing. Our highly integrated team of scientists, engineers, and operations personnel work together to ensure that key translational activities (e.g., initial knowledge transfer, tech transfer from process development to manufacturing, etc.) are completed using our robust and systematic procedures. 
To accomplish the fastest time to market with the highest quality product, our MSAT team performs quality assessments as early as possible in the product lifecycle. We employ our streamlined Quality by Design framework to help our partners identify quality target product profiles and CQAs early and extrapolate the Critical Material Attributes (CMAs) and Critical Process Parameters (CPPs) necessary to establish an effective production process for clinical delivery.  
Our hybrid, people-in-plant model enables truly collaborative partnerships where our partners can take part in the evolution of their biotherapies. Through this transparent paradigm, partners can work alongside our MSAT team to offer insight into their novel drug product and gain exposure to how we transform the production process from development stage into GMP manufacturing. 
Our emphasis on single-use technologies allows our MSAT team to achieve higher flexibility, efficiency, and product quality in the scale-up and manufacturing process. This also significantly reduces the time to clinic by eliminating the need to perform cleaning and sterilization validation studies.
Our MSAT team looks at implementing manufacturing methods that can be adequately scaled up or out based on the stage of development and the intended product delivery strategy. We have experience delivering patient specific and off-the-shelf therapies.  
Using a Quality by Design approach, BioCentriq prepares each product for process validation starting at pre-IND. It is important to build the foundation early with a defined Quality Target Product Profile and critical quality attributes. Those attributes and subsequent critical process parameters will be refined through the clinical results ahead of method validation and process performance qualification. 
Our MSAT engineers will steward each product through its clinical and commercial lifecycle. This includes providing hands-on training to key manufacturing and quality control personnel and drafting the batch documentation that will guide the production of every dose of product. 

MSAT Creates a Bridge to Successful Manufacturing

Image
Translates process development improvements for manufacturing. 
Virtual Instructor Led Training

Creates batch records and protocols to be executed in GMP. ​

​

BioCentriq Self-Paced Training Courses

Confirms and validates analytical methods to solidify QC strategy. 

Scientist in lab operating centrifuge with blue gloves on hands
Ensures compliance with GMP protocols and procedures. ​
Image
Translates process development improvements for manufacturing. 
Virtual Instructor Led Training

Creates batch records and protocols to be executed in GMP. ​

​

BioCentriq Self-Paced Training Courses

Confirms and validates analytical methods to solidify QC strategy. 

Scientist in lab operating centrifuge with blue gloves on hands
Ensures compliance with GMP protocols and procedures. ​
    CONTACT US

    The BioCentriq Team

    Combining years of specialized experience and technical expertise, the BioCentriq MSAT team thrives at the intersection of our clients and our process development and manufacturing teams.

    They employ an open communication style to help identify issues before they arise, understand the diverse needs of each project, and ensure a smooth process from start to finish.

    Get to know the team that will be pivotal in helping take your therapy to market.

    "I'm proud to say that what sets BioCentriq apart is our personnel. Our dedicated team is comprised of problem solvers dedicated to the unique needs of each project we work on."
    Image

    Mary Loveras

    Associate Director, MSAT

    "As we become an extension of your team, we assume the same goal: bringing your therapy to market quickly and safely—and we do that by adopting a quality first approach and ensuring true GMP readiness from every angle."
    Image

    Melissa Mastro

    Senior Engineer, MSAT

    Related news

    Transform Your Cell Therapy CDMO From Service Provider to Partner. Read now.

    Transform Your Cell Therapy CDMO From Service Provider to Partner

    BioCentriq Appoints Syed T. Husain as Chief Executive Officer

    From ISCT 2024: Watch Chathuranga De Silva, Ph.D., highlight BioCentriq’s achievements and LEAP™ Platform

    Watch Webinar On-Demand: End-to-End Automated Manufacturing of Low-Seed CAR-T Cells
    SEE ALL NEWS & EVENTS

    Get In Touch

    • This field is for validation purposes and should be left unchanged.